<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Spontaneous massive fetomaternal hemorrhage</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Spontaneous massive fetomaternal hemorrhage</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Spontaneous massive fetomaternal hemorrhage</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth J Moise Jr, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynne Uhl, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Aaron B Caughey, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Spontaneous fetomaternal hemorrhage (FMH) is defined as fetomaternal bleeding with no antecedent history of trauma and no clinical/histopathological evidence of abruption. The vast majority of spontaneous FMHs are small volume bleeds of no hemodynamic significance, but they may lead to alloimmunization. The frequency and volume of these types of bleeds increase with advancing gestational age and are highest at birth [<a href="#rid1">1</a>]. </p><p>Spontaneous massive (also called large) FMH is much less common. If FMH is acute and massive, it can result in rapid fetal hemodynamic collapse and death. If FMH is not massive but chronic (ie, intermittent repetitive), it can result in fetal anemia and hydrops fetalis over time, depending on the ability of the fetus to increase red cell production and compensate for ongoing blood loss. </p><p>This topic will review the clinical presentation, diagnosis, management, and prognosis of pregnancies complicated by spontaneous massive FMH. Small-volume FMH related to abruption and trauma and issues related to alloimmunization are reviewed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6826.html" rel="external">"Acute placental abruption: Pathophysiology, clinical features, diagnosis, and consequences"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6738.html" rel="external">"Initial evaluation and management of major trauma in pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6820.html" rel="external">"RhD alloimmunization in pregnancy: Overview"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6802.html" rel="external">"RhD alloimmunization in pregnancy: Management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6773.html" rel="external">"RhD alloimmunization: Prevention in pregnant and postpartum patients"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7921.html" rel="external">"Management of non-RhD red blood cell alloantibodies during pregnancy"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION/DIAGNOSIS</span><span class="headingEndMark"> — </span>We define massive FMH as one or both of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>FMH ≥20 percent of fetal blood volume, because this degree of blood loss is associated with fetal morbidity or mortality. (See <a class="local">'Outcome'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>FMH associated with middle cerebral artery peak systolic velocity (MCA-PSV) ≥1.5 multiples of the median (MoMs), because this correlates with moderate to severe fetal anemia. (See  <a class="medical medical_review" href="/z/d/html/6802.html" rel="external">"RhD alloimmunization in pregnancy: Management", section on 'Assess for severe anemia using MCA-PSV in fetuses at risk'</a>.)</p><p></p><p>A limitation of these definitions is that they do not account for the rate of blood loss or the chronicity of bleeding, which are additional but unmeasurable factors that affect fetal outcome. </p><p>There is no universally accepted threshold defining the volume of fetal erythrocytes in the maternal circulation that constitutes a small versus massive FMH. Although volumes up to 150 mL have been proposed to define massive FMH [<a href="#rid2">2</a>], we believe the volume of the bleed should be interpreted in relation to total fetoplacental blood volume, which correlates with fetal size and gestational age. Fetoplacental blood volume is approximately 120 mL/kg estimated fetal weight before 32 weeks of gestation and 100 mL/kg after 32 weeks [<a href="#rid3">3</a>]. Thus, a FMH of 40 mL for a 33 week fetus estimated to weigh 2000 grams represents a bleed of 20 mL/kg, which is 20 percent of its fetoplacental blood volume. </p><p class="headingAnchor" id="H3"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>The incidence of spontaneous massive FMH is unknown because it is uncommon, unpredictable, and signs and symptoms are neither specific nor reliably present [<a href="#rid4">4</a>]. In addition, studies have varied in their definition of massive FMH, types of patients (high versus low risk for FMH), and time in gestation when testing for FMH was performed (first, second, third trimester, or peripartum).</p><p class="bulletIndent1"><span class="glyph">●</span>When large numbers of RhD-negative patients were routinely tested for FMH after birth, the frequency of FMH &gt;80 mL ranged from 1/1146 to 1/1429 births [<a href="#rid2">2,5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of over 20,000 pregnancies within the Kaiser Permanente Northern California healthcare system in which flow cytometry analysis for fetal hemoglobin was performed over a 10-year period, there were 340 cases of clinically important FMH (approximately 1 in 1100 births) [<a href="#rid6">6</a>]. Clinically important FMH was defined as perinatal demise, any flow cytometry value of &gt;1 percent, or flow cytometry value of 0.1 to 1 percent with any of the following: preterm birth, neonatal anemia, or neonatal transfusion.  </p><p></p><p class="headingAnchor" id="H2011327003"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Bidirectional passage of minute numbers of red blood cells across the placenta is a normal physiologic event, even though the placenta is considered to be a barrier separating the maternal and fetal circulations [<a href="#rid1">1,7-13</a>]. The pathogenesis of spontaneous massive FMH is unclear. In a histologic study of placentas, parenchymal and retroplacental hemorrhage, intervillous thrombi, and infarction increased the likelihood that fetal cells would be found in the maternal circulation, and the extent of the abnormality correlated with the size of the hemorrhage [<a href="#rid14">14</a>]. However, many questions remain about the origin of these lesions and the factors that determine the number and volume of bleeding episodes.</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Spontaneous massive FMH can occur at any time in pregnancy or at birth. Fetal death may be the presenting sign of a massive acute bleed. Hydrops and/or abnormal fetal heart rate (FHR) patterns and/or decreased fetal movement may be the presenting signs of a massive but nonlethal acute FMH or chronic intermittent FMH resulting in a large cumulative blood loss over time. Some massive FMHs have no signs or symptoms.</p><p>Clinical scenarios that have led to a diagnosis of massive FMH include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decreased or absent fetal movement</strong>, which is the most common presenting symptom of massive FMH, reported by 27 and 54 percent of patients in two series [<a href="#rid15">15,16</a>]. The mother is usually otherwise asymptomatic, but symptoms suggestive of a transfusion reaction (fever, chills, nausea) occasionally occur [<a href="#rid15">15,17,18</a>]. During the course of the routine evaluation of decreased fetal movement, a sinusoidal FHR pattern  (<a class="graphic graphic_waveform graphicRef61189" href="/z/d/graphic/61189.html" rel="external">waveform 1</a>) and/or hydrops fetalis may be noted. Additional FHR patterns that have been described include absence of accelerations, recurrent late decelerations [<a href="#rid15">15,16,19,20</a>], and fetal tachycardia [<a href="#rid21">21</a>]. However, if the fetus is able to sufficiently compensate for the blood loss, the FHR pattern and biophysical profile score may be normal. (See  <a class="medical medical_review" href="/z/d/html/444.html" rel="external">"Decreased fetal movement: Diagnosis, evaluation, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unexplained neonatal anemia</strong> [<a href="#rid15">15,22</a>] – Massive peripartum FMH resulting in neonatal anemia has been described in approximately 1 in 9000 deliveries [<a href="#rid16">16</a>]. In severe cases, the newborn may be pale and in circulatory collapse at delivery. Laboratory results showing increased production of red blood cell precursors and increased circulating reticulocyte counts suggest that FMH occurred one to two days before birth [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unexpected fetal demise/stillbirth</strong> – Testing for FMH may be part of the evaluation of unexpected fetal demise. Up to 15 percent of fetal deaths are associated with massive FMH [<a href="#rid5">5,15,23</a>]. Causation is supported by FMH &gt;20 to 25 mL/kg fetal weight, and especially &gt;40 mL/kg fetal weight. In one series of 34 fetal deaths attributed to FMH, the mean total FMH was 67 mL/kg (55 percent of blood volume) and FMH exceeded 20 mL/kg (30 percent of blood volume) in 79 percent of cases [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/6827.html" rel="external">"Stillbirth: Incidence, risk factors, etiology, and prevention"</a> and  <a class="medical medical_review" href="/z/d/html/5402.html" rel="external">"Stillbirth: Maternal and fetal evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonimmune hydrops fetalis (NIHF)</strong> – NIHF may be discovered incidentally during prenatal sonography performed for standard obstetric indications, during a work-up for decreased fetal movement or abnormal results on antepartum fetal surveillance, during a work-up for uterine size greater than dates, or during monitoring of fetuses with, or at risk for, disorders associated with hydrops. The evaluation of NIHF may reveal severe fetal anemia (MCA-PSV ≥1.5 MoMs), and subsequent evaluation may reveal massive FMH as the cause [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/6794.html" rel="external">"Nonimmune hydrops fetalis", section on 'Anemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sinusoidal FHR pattern</strong> – A sinusoidal FHR pattern  (<a class="graphic graphic_waveform graphicRef61189" href="/z/d/graphic/61189.html" rel="external">waveform 1</a>) is strongly associated with severe fetal anemia from any cause and may be one of the first manifestations of massive FMH [<a href="#rid26">26</a>]. In a systematic review of 32 cases of severe fetal anemia (fetal or neonatal hemoglobin 1.9 to 7.2 g/dL [normal &gt;11 g/dL]) associated with FMH, the FHR pattern was reported as sinusoidal in 17 of the 24 cases in which a cardiotocogram was available; 5/24 patterns were nonreactive, 1/24 showed decelerations, and 1/24 showed tachycardia [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">A sinusoidal pattern may also be associated with hypoxia, acidosis, and asphyxia. (See  <a class="medical medical_review" href="/z/d/html/16663.html" rel="external">"Intrapartum category I, II, and III fetal heart rate tracings: Management", section on 'Category III pattern: Abnormal'</a>.) </p><p></p><p class="bulletIndent1">Of note, patterns closely resembling a sinusoidal pattern, termed pseudosinusoidal, have been described; however, there is no consensus on the exact definition of this pattern [<a href="#rid27">27</a>]. This pattern may be related to maternal opioid or sedative administration and is typically transient and associated with a good fetal outcome [<a href="#rid28">28</a>]. When the diagnosis of a sinusoidal versus pseudosinusoidal pattern is uncertain, fetal well-being is suggested by periods of moderate variability, occasional FHR accelerations, and/or a reassuring biophysical profile score. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine postpartum Kleihauer-Betke testing</strong> – This is performed to look for significant fetomaternal bleeding prior to anti-D-immune globulin administration in RhD-negative mothers [<a href="#rid29">29,30</a>]. (See  <a class="medical medical_review" href="/z/d/html/6773.html" rel="external">"RhD alloimmunization: Prevention in pregnant and postpartum patients"</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h1">CANDIDATES FOR FMH TESTING</span><span class="headingEndMark"> — </span>Massive FMH will only be detected if clinicians are aware of the clinical scenarios associated with the disorder and test for FMH [<a href="#rid22">22</a>]. Most of these clinical scenarios reflect the most severe end of the clinical spectrum; less severe cases are likely to be missed because they do not present with abnormal clinical findings and testing for FMH is not a routine prenatal or postnatal laboratory test.</p><p>Testing for massive FMH is appropriate in the following clinical settings, unless the reason for the finding is known [<a href="#rid31">31,32</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Nonimmune hydrops fetalis with MCA-PSV ≥1.5 MoMs</p><p class="bulletIndent1"><span class="glyph">●</span>Sinusoidal fetal heart rate (FHR) pattern with MCA-PSV ≥1.5 MoMs</p><p class="bulletIndent1"><span class="glyph">●</span>Fetal demise/stillbirth</p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal anemia</p><p></p><p>We also test RhD-negative patients after birth to ensure that they receive the appropriate dose of <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">anti-D immune globulin</a>. (See  <a class="medical medical_review" href="/z/d/html/6773.html" rel="external">"RhD alloimmunization: Prevention in pregnant and postpartum patients", section on 'Testing for fetomaternal bleeding'</a>.)</p><p>We do not routinely perform a maternal assay to detect FMH in all pregnancies with decreased fetal movement. We test for FMH as part of the evaluation of pregnant patients who present with decreased fetal movement who also have signs of fetal anemia (eg, sinusoidal FHR pattern, fetal hydrops with MCA-PSV ≥1.5 MoMs). Although some clinicians test for FMH in all cases of persistently decreased fetal movement, the cost-effectiveness of this approach has not been established [<a href="#rid33">33,34</a>]. (See  <a class="medical medical_review" href="/z/d/html/444.html" rel="external">"Decreased fetal movement: Diagnosis, evaluation, and management"</a>.)</p><p class="headingAnchor" id="H784295482"><span class="h1">MEASURING THE VOLUME OF FMH</span><span class="headingEndMark"> — </span>Two tests are available for estimating the volume of FMH: the Kleihauer-Betke acid elution assay and flow cytometry [<a href="#rid35">35</a>]. A survey of 2067 laboratories indicated that 96 percent use the Kleihauer-Betke assay, and only 4 percent use flow cytometry in cases of FMH [<a href="#rid36">36</a>]. </p><p>Both assays are based on identification of hemoglobin F, the predominant fetal hemoglobin. However, up to 1 percent of adult hemoglobin is hemoglobin F. The hemoglobin F is produced by a small number of erythroid precursors; their progeny in the blood are called "F cells" and also contain hemoglobin A. These F cells can lead to overestimation of the volume of fetal blood in maternal blood. Differentiating adult F cells from fetal hemoglobin F containing red blood cells is especially important in pregnancies of patients with some hematologic disorders, such as sickle cell disease, which can be associated with a large number of F cells. For this reason and because of other factors that may affect the estimated volume of FMH (discussed below), consultation with the Blood Bank can be helpful when the clinician receives a report of FMH. (See  <a class="medical medical_review" href="/z/d/html/7072.html" rel="external">"Structure and function of normal hemoglobins"</a> and  <a class="medical medical_review" href="/z/d/html/90749.html" rel="external">"Fetal hemoglobin (Hb F) in health and disease"</a>.)</p><p class="headingAnchor" id="H784295544"><span class="h2">Kleihauer-Betke assay</span><span class="headingEndMark"> — </span>The Kleihauer-Betke acid elution assay historically has been the main diagnostic test for detection and quantitation of FMH [<a href="#rid37">37</a>]. Red blood cells from the maternal circulation are fixed to a slide that is exposed to an acidic pH solution. Adult red blood cells become "ghost" cells since hemoglobin A is soluble and eluted across membrane defects at a low pH. Fetal red blood cells remain pink because hemoglobin F is stable at pHs in this range  (<a class="graphic graphic_picture graphicRef71762" href="/z/d/graphic/71762.html" rel="external">picture 1</a>). </p><p>A laboratory technician looking through a microscope counts a minimum of 2000 cells and reports the result as the percentage of fetal red blood cells in the total sample. The percentage is represented as a decimal fraction (ie, 5 percent = 0.05). The volume of fetal whole blood (mL) in the maternal circulation is: (decimal fraction of fetal cells) X (maternal hematocrit [%] divided by fetal hematocrit [%]) X (maternal blood volume mL).</p><p>In the usual clinical scenario, the maternal blood volume and the fetal hematocrit are not known, and most laboratories do not request the maternal hematocrit for the calculation. The maternal blood volume is often assumed to be 5000 mL, yielding the following formula to calculate the volume of fetal whole blood (mL) in the maternal circulation: (decimal fraction of fetal cells) X 5000 mL. Thus, if the Kleihauer-Betke result is 0.1 percent, the FMH calculation is (0.001 X 5000) = 5 mL of fetal whole blood.</p><p>Several factors can be associated with an underestimation of the volume of the FMH. The test is labor intensive with significant interoperator and intraoperator variability. Technical issues, such as smears that are too thick, inadequate drying times, or short buffering times, can contribute to poor fetal cell staining [<a href="#rid36">36</a>]. A decreasing fetal hemoglobin concentration in the fetal red cells with advancing gestational age may also contribute to poor staining of these cells [<a href="#rid33">33</a>]. Another factor that may distort the estimate is that the lifespan of fetal red blood cells in the maternal circulation is shortened if there is ABO incompatibility or alloimmunization. Finally, the use of an assumed maternal blood volume of 5 liters in the usual calculations will underestimate the actual volume of the FMH in the overweight pregnant patient.</p><p>Overestimation of the FMH volume can also occur. The presence of fetal hemoglobin in maternal red cells increases with advancing gestational age, reaching levels as high as 7 percent by 32 weeks gestation in 25 percent of pregnant patients [<a href="#rid38">38</a>]. The use of an assumed maternal blood volume of 5 liters in the usual calculations will overestimate the actual volume of the FMH in the underweight pregnant patient.</p><p>Variations in the formula for estimating FMH and in the assumptions used in the calculating of FMH have been published. A comparison of these formulas when fetal cells comprised 3 percent of cells in the maternal sample yielded FMH estimates ranging from 108 to 162 mL [<a href="#rid33">33</a>]. </p><p class="headingAnchor" id="H784295638"><span class="h2">Flow cytometry</span><span class="headingEndMark"> — </span>Flow cytometry is another assay for detecting and quantitating FMH [<a href="#rid39">39</a>]. A monoclonal antibody to hemoglobin F is conjugated to a fluorochrome and used to detect fetal hemoglobin in permeabilized cells as they pass through the channel of a flow cytometer. Comparative analysis of flow cytometry and the Kleihauer-Betke test has shown that flow cytometry is more accurate, more reproducible, and less labor intensive [<a href="#rid40">40</a>]. For this reason, many laboratories have converted to this assay for detecting FMH.</p><p>Calculation of FMH using flow cytometry is subject to the same limitations as the Kleihauer-Betke test: inability to measure the maternal blood volume and interference with persistence of fetal hemoglobin in some adult red blood cells (F cells). Dual-parameter flow cytometry can alleviate the issue with maternal F cells noted in such disease states as hemoglobinopathies and thalassemias. A second antibody is used to detect erythrocyte antigens unique to adult red cells, such as carbonic anhydrase: adult red cells are carbonic anhydrase positive, whether hemoglobin F positive or negative. Fetal cells are negative for carbonic anhydrase; thus, hemoglobin F positive/carbonic anhydrase negative cells are fetal and gated for a positive response. However, this system can be imprecise because some adults with hemoglobinopathies appear to have some F cells with a fetal phenotype (hemoglobin F positive/carbonic anhydrase negative) [<a href="#rid41">41,42</a>].</p><p>The flow cytometry equation for calculating the volume (mL) of fetal packed red blood cells in the maternal circulation is [<a href="#rid39">39</a>]: (% positive events) X (1800 mL) divided by 100 X (122/100), where 1800 mL is the estimated average maternal red blood cell volume based on a maternal hematocrit of 36 percent and 122/100 is an adjustment to take into account that fetal red blood cells are usually approximately 20 percent larger than adult red blood cells. Multiplying this value by a factor of two yields the volume (mL) of whole blood FMH since the normal fetal hematocrit is approximately 50 percent. As an example, a flow cytometry result of 0.1 percent positive events would result in the following calculation: (0.1 X 1800)/100 = 1.8 X 122/100 = 2.16 mL X 2 = 4.32 mL whole blood volume FMH. The estimated total fetoplacental blood volume can be calculated by multiplying the estimated fetal weight in kilograms (based on ultrasound parameters) by 100 mL/kg (the fetoplacental blood volume per kilogram fetal weight after 32 weeks) or 125 mL/kg (the fetoplacental blood volume per kilogram fetal weight before 32 weeks). The percent of fetoplacental blood volume represented by the FMH would be (whole blood volume of FMH in mL) divided by (estimated fetal weight in kg) X (100 or 125 mL/kg). </p><p class="headingAnchor" id="H17"><span class="h1">MANAGEMENT OF CASES DETECTED ANTENATALLY</span><span class="headingEndMark"> — </span>The author's approach to management of antenatally detected cases of spontaneous massive FMH is illustrated by the following algorithm  (<a class="graphic graphic_algorithm graphicRef73675" href="/z/d/graphic/73675.html" rel="external">algorithm 1</a>) and discussed below. Management depends on fetal status, degree of anemia, and gestational age.</p><p class="headingAnchor" id="H1730644723"><span class="h2">Nonreassuring tests of fetal well-being</span><span class="headingEndMark"> — </span>Patients who present with nonreassuring standard tests of fetal well-being (biophysical profile, nonstress test) typically require urgent delivery, regardless of the cause. </p><p class="headingAnchor" id="H2090333725"><span class="h2">MCA-PSV ≥1.5 MoMs, FMH &gt;20 percent, and reassuring fetal testing</span><span class="headingEndMark"> — </span>The author's approach in these cases  (<a class="graphic graphic_algorithm graphicRef73675" href="/z/d/graphic/73675.html" rel="external">algorithm 1</a>) is based on expert opinion and guided by personal experience with a few cases of massive FMH, review of published case reports and small case series, extrapolation of principles of management of fetal anemia from other causes, available resources, and shared decision making that considers the morbidity of preterm birth, the morbidity of in utero therapy, and the uncertain clinical course of expectant management. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>≥32 weeks of gestation</strong> – For pregnancies ≥32 weeks with middle cerebral artery peak systolic velocity (MCA-PSV) ≥1.5 multiples of the median (MoMs) and FMH ≥20 percent of the fetal blood volume, we perform immediate cesarean birth, with blood available for prompt neonatal transfusion. The morbidity of preterm birth at this gestational age is probably less than the risk of in utero transfusion or recurrent FMH during expectant management.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>&lt;32 weeks of gestation</strong> – For pregnancies &lt;32 weeks of gestation with FMH ≥20 percent of blood volume, especially with signs of severe anemia (ie, MCA-PSV ≥1.5 plus hydrops fetalis), we perform an intravascular transfusion (IVT) of donor red blood cells to acutely correct fetal anemia, as transfusion is probably associated with lower morbidity and mortality than birth &lt;32 weeks [<a href="#rid43">43-45</a>]. A course of antenatal corticosteroids is administered at the same time because these pregnancies are at increased risk for preterm birth. (See  <a class="medical medical_review" href="/z/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"</a>.)</p><p></p><p class="bulletIndent1">A second IVT may be needed, but timing is difficult to determine. We perform daily Kleihauer-Betke or flow cytometry testing, MCA-PSV, and biophysical profiles until IVTs are no longer deemed necessary, which we consider to be after seven consecutive days of stable or improving results and reassuring biophysical profile scores [<a href="#rid45">45-47</a>]. Diagnosis of ongoing FMH is challenging after transfusion because the transfused cells contain adult hemoglobin and thus are not detected by Kleihauer-Betke or flow cytometry tests. </p><p></p><p class="bulletIndent1">The MCA-PSV should drop within 24 hours of correction of the fetal anemia by the IVT. If we observe MCA-PSV≥1.5 MoMs or a 5 percentage point increase in FMH (eg, from 22 percent to 27 percent) at any time during the seven days, we assume there is ongoing fetomaternal bleeding and perform a second IVT. Daily Kleihauer-Betke or flow cytometry testing, MCA-PSV, and biophysical profiles are performed for another seven days. If MCA-PSV≥1.5 MoMs or a 5 percentage point increase in FMH occurs again at any time during the seven days, we deliver the fetus because we believe repeated IVTs are unlikely to be successful in cases with ongoing FMH [<a href="#rid48">48</a>]. The success rate in significantly prolonging gestation to term after two IVTs for FMH appears to be approximately 50 percent.</p><p></p><p class="bulletIndent1">In patients with seven consecutive days of stable or improving results after one or two IVTs, we monitor the fetus closely until birth. These cases are rare and no guidelines for antepartum fetal surveillance exist. The author performs a nonstress test or biophysical profile twice weekly and Doppler ultrasound MCA-PSV weekly until delivery in an attempt to identify recurrent significant FMH.</p><p></p><p class="bulletIndent1">A review of chronic massive FMH with fetal hydrops treated by IVT reported overall perinatal survival in 12 of 14 cases (86 percent survival) [<a href="#rid49">49</a>]. Ten patients required two transfusions, and five required at least three procedures. The gestational age at onset was 26.6±2.1 weeks, and the gestational age at birth was 34.2±4.2 weeks. Although these results are promising, the series is small, and other clinicians have reported unsuccessful outcomes, including perinatal death and long-term disability [<a href="#rid33">33,48</a>]. Therefore, use of such therapy should be limited to centers with experience in both serial MCA Doppler assessment and IVTs. </p><p></p><p class="headingAnchor" id="H19"><span class="h2">MCA-PSV ≥1.5 MoMs, FMH &lt;20 percent, and reassuring fetal testing</span><span class="headingEndMark"> — </span>These pregnancies are evaluated with daily Kleihauer-Betke or flow cytometry testing, MCA-PSV, and biophysical profiles for seven days. A repeat MCA-PSV ≥1.5 MoM or a 5 percent absolute increase in FMH at any time during the seven days is a sign of chronic FMH. We manage such patients as described above: deliver if ≥32 weeks and perform IVT if &lt;32 weeks  (<a class="graphic graphic_algorithm graphicRef73675" href="/z/d/graphic/73675.html" rel="external">algorithm 1</a>). </p><p>If the MCA-PSV and Kleihauer-Betke or flow cytometry testing results improve during the seven days, we follow the fetus closely until birth with a nonstress test or biophysical profile twice weekly and Doppler ultrasound MCA-PSV weekly in an attempt to identify recurrent significant FMH.</p><p class="headingAnchor" id="H822007204"><span class="h1">DELIVERY</span><span class="headingEndMark"> — </span>We recommend cesarean birth to prevent any further deterioration in the fetal status due to ongoing intrapartum FMH. In addition:</p><p class="bulletIndent1"><span class="glyph">●</span>The pediatric team should be notified about the potential for neonatal anemia. Red cells crossmatched to maternal serum should be available for immediate neonatal transfusion. This should include standard processing of blood for neonatal transfusions (leukoreduction and irradiation).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The placenta should be sent for histopathologic evaluation, which might suggest a cause for the FMH. Although rare, massive FMH has been associated with intraplacental choriocarcinoma [<a href="#rid50">50-55</a>].</p><p></p><p class="headingAnchor" id="H20"><span class="h1">OUTCOME</span></p><p class="headingAnchor" id="H1151398866"><span class="h2">Maternal</span><span class="headingEndMark"> — </span>The mother is at risk of alloimmunization to red cell antigens. (See  <a class="medical medical_review" href="/z/d/html/7921.html" rel="external">"Management of non-RhD red blood cell alloantibodies during pregnancy"</a>.) </p><p>There is a single case report of severe preeclampsia and HELLP (Hemolysis, Elevated Liver function tests, Low Platelets) syndrome developing within 24 hours after blunt abdominal trauma with massive FMH and fetal intracranial bleeding [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H846593508"><span class="h2">Fetal/neonatal</span><span class="headingEndMark"> — </span>Fetal/neonatal outcome depends upon the rapidity of fetal blood loss and the volume of the hemorrhage relative to total fetoplacental blood volume [<a href="#rid57">57,58</a>]. As discussed above, massive FMH is more likely to be fatal if blood loss occurs over minutes rather than hours, days, or weeks. Although a critical prognostic factor, the rate of fetomaternal bleeding in human pregnancies is generally impossible to assess clinically, unless the fetus is hydropic, which suggests chronic anemia.</p><p>Reported morbidity and mortality rates were derived from case reports and case series involving a range of gestational ages, both acute and chronic bleeds, and wide diversity in clinical presentation and management (in utero transfusion, expectant management, early delivery).</p><p>The range of short-term outcomes reported in the literature is illustrated by the following examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a French study, the fetal death rate was 25 percent (two of eight fetuses) for FMH 40 to 80 mL/kg and 66 percent (four of six fetuses) for FMH ≥80 mL/kg (fetoplacental blood volume averages approximately 100 mL/kg fetal weight [<a href="#rid59">59,60</a>]).</p><p></p><p class="bulletIndent1">Morbidity occurred primarily in the 23 fetuses calculated to have bled ≥20 mL/kg (ie, &gt;20 percent of fetoplacental blood volume) and included: induced preterm birth (17 percent), admission to the neonatal intensive care unit (35 percent), and neonatal transfusion (22 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another French study, 42 children were delivered of pregnancies complicated by ≥20 mL FMH, and 23 had FMH ≥20 mL/kg [<a href="#rid5">5</a>]. In the short-term, FMH 20 to 40 mL/kg was associated with an adverse outcome in five of nine cases, FMH 40 to 80 mL/kg was associated with an adverse outcome in five of eight cases (including two stillbirths), and FMH &gt;80 mL/kg resulted in adverse outcome in all six cases (including four stillbirths).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For FMH ≥150 mL, pooled data from two studies yielded a perinatal death rate of 37 percent (25 of 67) [<a href="#rid2">2,11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A review of 134 cases of FMH &gt;50 mL noted that 13 live-born infants had evidence of neurologic dysfunction, 10 had respiratory distress syndrome, 7 had persistent pulmonary hypertension, 4 developed disseminated intravascular coagulation, and 2 each developed pulmonary hemorrhage, cardiomegaly, and renal dysfunction [<a href="#rid15">15</a>]. Seventeen intrauterine fetal transfusions were performed in nine fetuses, eight of whom survived.</p><p></p><p>Long-term pediatric outcome after massive FMH is less well described. In one French series, 31 children were available for follow-up at a median age of 59 months (range 18 to 107 months) [<a href="#rid5">5</a>]. No long-term neurologic sequelae related to FMH were noted; however, the authors acknowledged their small sample size and a resulting wide confidence interval limited their ability to detect poor outcome (95% CI 0-11.6 percent). Other series have described neurologic injury in 0 to 35 percent of surviving infants [<a href="#rid2">2,11,16</a>]. In survivors of hemodynamic collapse from massive FMH, an increased risk for long-term neurodevelopmental impairment is certainly plausible. (See  <a class="medical medical_review" href="/z/d/html/6205.html" rel="external">"Etiology and pathogenesis of neonatal encephalopathy"</a> and  <a class="medical medical_review" href="/z/d/html/6216.html" rel="external">"Clinical features, diagnosis, and treatment of neonatal encephalopathy"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">RECURRENCE</span><span class="headingEndMark"> — </span>Recurrent significant FMH in successive pregnancies has been described primarily in case reports [<a href="#rid61">61-63</a>]. In a series of 143 patients with FMH who had 210 subsequent pregnancies, fetomaternal hemorrhage recurred in one pregnancy (0.5 percent) [<a href="#rid6">6</a>].</p><p>There is no evidence on which to base a recommendation for following these patients. Attention to fetal activity and prompt evaluation of decreased fetal activity is a reasonable approach [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/444.html" rel="external">"Decreased fetal movement: Diagnosis, evaluation, and management"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition/diagnosis</strong> – We define massive fetomaternal hemorrhage (FMH) as one or both of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>FMH ≥20 percent of fetal blood volume, because this degree of blood loss is associated with fetal morbidity or mortality. (See <a class="local">'Outcome'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>FMH associated with middle cerebral artery peak systolic velocity (MCA-PSV) ≥1.5 multiples of the median (MoMs), because this correlates with moderate to severe fetal anemia. (See <a class="local">'Definition/diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Spontaneous massive FMH can occur at any time during pregnancy or at birth. Fetal death may be the presenting sign of a massive acute bleed. Hydrops and/or abnormal fetal heart rate (FHR) patterns and/or decreased fetal movement may be the presenting signs of a massive but nonlethal acute FMH or intermittent FMH resulting in a large cumulative blood loss over time. Some massive FMHs have no signs or symptoms. In the antepartum period, decreased or absent fetal movement is the most common presenting symptom. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidates for evaluation for FMH</strong> – Massive FMH will only be detected if clinicians are aware of the clinical scenarios associated with the disorder and test for FMH. Most of these clinical scenarios reflect the most severe end of the clinical spectrum; less severe cases are likely to be missed because they do not present with abnormal clinical findings and testing for FMH is not a routine prenatal or postnatal laboratory test.</p><p></p><p class="bulletIndent1">We suggest testing for massive FMH in the following clinical settings, unless the reason for the finding is known:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonimmune hydrops fetalis with MCA-PSV ≥1.5 MoMs</p><p class="bulletIndent2"><span class="glyph">•</span>Sinusoidal FHR pattern with MCA-PSV ≥1.5 MoMs</p><p class="bulletIndent2"><span class="glyph">•</span>Fetal demise/stillbirth</p><p class="bulletIndent2"><span class="glyph">•</span>Neonatal anemia</p><p></p><p class="bulletIndent1">We also test RhD-negative patients after birth to ensure that they receive the appropriate dose of <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">anti-D immune globulin</a>. (See <a class="local">'Candidates for FMH testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tests for FMH</strong> – Either a Kleihauer-Betke acid elution assay or flow cytometry can be used for diagnosing FMH. The volume of fetal blood loss should be calculated as a percentage of the estimated fetoplacental blood volume. (See <a class="local">'Measuring the volume of FMH'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– Our approach to suspected spontaneous FMH with reassuring fetal testing is illustrated by the algorithm  (<a class="graphic graphic_algorithm graphicRef73675" href="/z/d/graphic/73675.html" rel="external">algorithm 1</a>). Patients with nonreassuring fetal testing typically require urgent delivery, regardless of the cause. (See <a class="local">'Management of cases detected antenatally'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delivery </strong>– We recommend cesarean birth to prevent any further deterioration in the fetal status due to ongoing FMH. The pediatric team should be notified about the potential for neonatal anemia and the placenta should be sent for histopathologic evaluation. (See <a class="local">'Delivery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome</strong> – Fetal/neonatal outcome depends upon the rapidity of fetal blood loss and the volume of the hemorrhage relative to total fetoplacental blood volume. (See <a class="local">'Outcome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrence</strong> – Recurrent significant FMH in successive pregnancies has been described in case reports. (See <a class="local">'Recurrence'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bowman JM, Pollock JM, Penston LE. Fetomaternal transplacental hemorrhage during pregnancy and after delivery. Vox Sang 1986; 51:117.</a></li><li><a class="nounderline abstract_t">de Almeida V, Bowman JM. Massive fetomaternal hemorrhage: Manitoba experience. Obstet Gynecol 1994; 83:323.</a></li><li><a class="nounderline abstract_t">Le Ray C, Hudon L, Leduc L. Fetal transfusion of red blood cells for alloimmunization: validity of a published equation. Fetal Diagn Ther 2009; 25:379.</a></li><li><a class="nounderline abstract_t">Stefanovic V. Fetomaternal hemorrhage complicated pregnancy: risks, identification, and management. Curr Opin Obstet Gynecol 2016; 28:86.</a></li><li><a class="nounderline abstract_t">Rubod C, Deruelle P, Le Goueff F, et al. Long-term prognosis for infants after massive fetomaternal hemorrhage. Obstet Gynecol 2007; 110:256.</a></li><li><a class="nounderline abstract_t">Boller MJ, Moore GS, Hung YY, et al. Fetomaternal hemorrhage: evaluation of recurrence within a large integrated healthcare system. Am J Obstet Gynecol 2021; 225:540.e1.</a></li><li><a class="nounderline abstract_t">Bianchi DW, Romero R. Biological implications of bi-directional fetomaternal cell traffic: a summary of a National Institute of Child Health and Human Development-sponsored conference. J Matern Fetal Neonatal Med 2003; 14:123.</a></li><li><a class="nounderline abstract_t">Lo YM, Lau TK, Chan LY, et al. Quantitative analysis of the bidirectional fetomaternal transfer of nucleated cells and plasma DNA. Clin Chem 2000; 46:1301.</a></li><li><a class="nounderline abstract_t">Dana M, Fibach E. Fetal Hemoglobin in the Maternal Circulation - Contribution of Fetal Red Blood Cells. Hemoglobin 2018; 42:138.</a></li><li><a class="nounderline abstract_t">Jørgensen J. Feto-maternal bleeding. During pregnancy and at delivery. Acta Obstet Gynecol Scand 1977; 56:487.</a></li><li><a class="nounderline abstract_t">Sebring ES, Polesky HF. Fetomaternal hemorrhage: incidence, risk factors, time of occurrence, and clinical effects. Transfusion 1990; 30:344.</a></li><li><a class="nounderline abstract_t">Dupre AR, Morrison JC, Martin JN Jr, et al. Clinical application of the Kleihauer-Betke test. J Reprod Med 1993; 38:621.</a></li><li><a class="nounderline abstract_t">Medearis AL, Hensleigh PA, Parks DR, Herzenberg LA. Detection of fetal erythrocytes in maternal blood post partum with the fluorescence-activated cell sorter. Am J Obstet Gynecol 1984; 148:290.</a></li><li><a class="nounderline abstract_t">Devi B, Jennison RF, Langley FA. Significance of placental pathology in transplacental haemorrhage. J Clin Pathol 1968; 21:322.</a></li><li><a class="nounderline abstract_t">Giacoia GP. Severe fetomaternal hemorrhage: a review. Obstet Gynecol Surv 1997; 52:372.</a></li><li><a class="nounderline abstract_t">Christensen RD, Lambert DK, Baer VL, et al. Severe neonatal anemia from fetomaternal hemorrhage: report from a multihospital health-care system. J Perinatol 2013; 33:429.</a></li><li><a class="nounderline abstract_t">Murphy KW, Venkatraman N, Stevens J. Limitations of ultrasound in the diagnosis of fetomaternal haemorrhage. BJOG 2000; 107:1317.</a></li><li><a class="nounderline abstract_t">Glasser L, West JH, Hagood RM. Incompatible fetomaternal transfusion with maternal intravascular lysis. Transfusion 1970; 10:322.</a></li><li><a class="nounderline abstract_t">Modanlou HD, Freeman RK, Ortiz O, et al. Sinusoidal fetal heart rate pattern and severe fetal anemia. Obstet Gynecol 1977; 49:537.</a></li><li><a class="nounderline abstract_t">Bellussi F, Perolo A, Ghi T, et al. Diagnosis of Severe Fetomaternal Hemorrhage with Fetal Cerebral Doppler: Case Series and Systematic Review. Fetal Diagn Ther 2017; 41:1.</a></li><li><a class="nounderline abstract_t">Nicolaides KH, Sadovsky G, Visser GH. Heart rate patterns in normoxemic, hypoxemic, and anemic second-trimester fetuses. Am J Obstet Gynecol 1989; 160:1034.</a></li><li><a class="nounderline abstract_t">Stroustrup A, Plafkin C, Savitz DA. Impact of physician awareness on diagnosis of fetomaternal hemorrhage. Neonatology 2014; 105:250.</a></li><li><a class="nounderline abstract_t">Laube DW, Schauberger CW. Fetomaternal bleeding as a cause for "unexplained" fetal death. Obstet Gynecol 1982; 60:649.</a></li><li><a class="nounderline abstract_t">O'Leary BD, Walsh CA, Fitzgerald JM, et al. The contribution of massive fetomaternal hemorrhage to antepartum stillbirth: a 25-year cross-sectional study. Acta Obstet Gynecol Scand 2015; 94:1354.</a></li><li><a class="nounderline abstract_t">Sueters M, Arabin B, Oepkes D. Doppler sonography for predicting fetal anemia caused by massive fetomaternal hemorrhage. Ultrasound Obstet Gynecol 2003; 22:186.</a></li><li><a class="nounderline abstract_t">Watanabe N, Jwa SC, Ozawa N, Sago H. Sinusoidal heart rate patterns as a manifestation of massive fetomaternal hemorrhage in a monochorionic-diamniotic twin pregnancy: a case report. Fetal Diagn Ther 2010; 27:168.</a></li><li><a class="nounderline abstract_t">Modanlou HD, Murata Y. Sinusoidal heart rate pattern: Reappraisal of its definition and clinical significance. J Obstet Gynaecol Res 2004; 30:169.</a></li><li><a class="nounderline abstract_t">Hofmeyr GJ, Sonnendecker EW. Sinusoidal versus pseudosinusoidal fetal heart rate patterns. S Afr Med J 1983; 64:19.</a></li><li><a class="nounderline abstract_t">Peedin AR, Mazepa MA, Park YA, et al. Two cases of asymptomatic massive fetomaternal hemorrhage. Transfus Apher Sci 2015; 52:208.</a></li><li><a class="nounderline abstract_t">Post GR, Lazarchick J, Singh ZN. Clinically silent massive fetomaternal hemorrhage: important lessons from an illustrative case. Lab Hematol 2012; 18:11.</a></li><li><a class="nounderline abstract_t">Stillbirth Collaborative Research Network Writing Group. Causes of death among stillbirths. JAMA 2011; 306:2459.</a></li><li><a class="nounderline abstract_t">Management of Stillbirth: Obstetric Care Consensus No, 10. Obstet Gynecol 2020; 135:e110.</a></li><li><a class="nounderline abstract_t">Wylie BJ, D'Alton ME. Fetomaternal hemorrhage. Obstet Gynecol 2010; 115:1039.</a></li><li><a class="nounderline abstract_t">Audette MC, Mclean K, Malkani N, et al. Diagnostic accuracy of Kleihauer-Betke (Kb) testing to predict fetal outcomes associated with fetomaternal hemorrhage: a retrospective cohort study. J Perinatol 2022; 42:91.</a></li><li><a class="nounderline abstract_t">Kim YA, Makar RS. Detection of fetomaternal hemorrhage. Am J Hematol 2012; 87:417.</a></li><li><a class="nounderline abstract_t">Karafin MS, Glisch C, Souers RJ, et al. Use of Fetal Hemoglobin Quantitation for Rh-Positive Pregnant Females: A National Survey and Review of the Literature. Arch Pathol Lab Med 2019; 143:1539.</a></li><li><a class="nounderline abstract_t">KLEIHAUER E, BRAUN H, BETKE K. [Demonstration of fetal hemoglobin in erythrocytes of a blood smear]. Klin Wochenschr 1957; 35:637.</a></li><li><a class="nounderline abstract_t">Popat N, Wood WG, Weatherall DJ, Turnbull AC. Pattern of maternal F-cell production during pregnancy. Lancet 1977; 2:377.</a></li><li><a class="nounderline abstract_t">Dziegiel MH, Nielsen LK, Berkowicz A. Detecting fetomaternal hemorrhage by flow cytometry. Curr Opin Hematol 2006; 13:490.</a></li><li><a class="nounderline abstract_t">Bromilow IM, Duguid JK. Measurement of feto-maternal haemorrhage: a comparative study of three Kleihauer techniques and tow flow cytometry methods. Clin Lab Haematol 1997; 19:137.</a></li><li><a class="nounderline abstract_t">Prus E, Fibach E. Heterogeneity of F cells in β-thalassemia. Transfusion 2013; 53:499.</a></li><li><a class="nounderline abstract_t">Othman J, Orellana D, Chen LS, et al. The presence of F cells with a fetal phenotype in adults with hemoglobinopathies limits the utility of flow cytometry for quantitation of fetomaternal hemorrhage. Cytometry B Clin Cytom 2018; 94:695.</a></li><li><a class="nounderline abstract_t">Rubod C, Houfflin V, Belot F, et al. Successful in utero treatment of chronic and massive fetomaternal hemorrhage with fetal hydrops. Fetal Diagn Ther 2006; 21:410.</a></li><li><a class="nounderline abstract_t">Stefanovic V, Paavonen J, Halmesmäki E, et al. Two intrauterine rescue transfusions in treatment of severe fetomaternal hemorrhage in the early third trimester. Clin Case Rep 2013; 1:59.</a></li><li><a class="nounderline abstract_t">Votino C, Mirlesse V, Gourand L, et al. Successful treatment of a severe second trimester fetomaternal hemorrhage by repeated fetal intravascular transfusions. Fetal Diagn Ther 2008; 24:503.</a></li><li><a class="nounderline abstract_t">Friszer S, Cortey A, Pierre F, Carbonne B. Using middle cerebral artery peak systolic velocity to time in utero transfusions in fetomaternal hemorrhage. Obstet Gynecol 2010; 115:1036.</a></li><li><a class="nounderline abstract_t">Mari G, Zimmermann R, Moise KJ Jr, Deter RL. Correlation between middle cerebral artery peak systolic velocity and fetal hemoglobin after 2 previous intrauterine transfusions. Am J Obstet Gynecol 2005; 193:1117.</a></li><li><a class="nounderline abstract_t">Sifakis S, Koukoura O, Konstantinidou AE, et al. Sonographic findings in severe fetomaternal transfusion. Arch Gynecol Obstet 2010; 281:241.</a></li><li><a class="nounderline abstract_t">Troìa L, Al-Kouatly HB, McCurdy R, et al. The Recurrence Risk of Fetomaternal Hemorrhage. Fetal Diagn Ther 2019; 45:1.</a></li><li><a class="nounderline abstract_t">Henningsen AK, Maroun LL, Havsteen H, Svare J. Massive fetomaternal hemorrhage caused by an intraplacental choriocarcinoma: a case report. Case Rep Med 2010; 2010:767218.</a></li><li><a class="nounderline abstract_t">Ryu N, Ogawa M, Matsui H, et al. The clinical characteristics and early detection of postpartum choriocarcinoma. Int J Gynecol Cancer 2015; 25:926.</a></li><li><a class="nounderline abstract_t">Aso K, Tsukimori K, Yumoto Y, et al. Prenatal findings in a case of massive fetomaternal hemorrhage associated with intraplacental choriocarcinoma. Fetal Diagn Ther 2009; 25:158.</a></li><li><a class="nounderline abstract_t">Santamaria M, Benirschke K, Carpenter PM, et al. Transplacental hemorrhage associated with placental neoplasms. Pediatr Pathol 1987; 7:601.</a></li><li><a class="nounderline abstract_t">Nagel HT, Vandenbussche FP, Smit VT, et al. Intraplacental choriocarcinoma as an unexpected cause of intrauterine death at term. Int J Gynecol Cancer 2007; 17:1337.</a></li><li><a class="nounderline abstract_t">She Q, Cheng Z, El-Chaar D, et al. Intraplacental choriocarcinoma coexisting with fetomaternal hemorrhage: Case report, chemotherapy management, and literature review. Medicine (Baltimore) 2018; 97:e9977.</a></li><li><a class="nounderline abstract_t">Faber VJ, Klumper FJ, Scherjon S, van Wijngaarden WJ. Severe pre-eclampsia and HELLP syndrome after massive fetomaternal hemorrhage following blunt abdominal trauma. Pregnancy Hypertens 2011; 1:197.</a></li><li><a class="nounderline abstract_t">Brace RA. Mechanisms of fetal blood volume restoration after slow fetal hemorrhage. Am J Physiol 1989; 256:R1040.</a></li><li><a class="nounderline abstract_t">Brace RA, Cheung CY. Fetal blood volume restoration following rapid fetal hemorrhage. Am J Physiol 1990; 259:H567.</a></li><li><a class="nounderline abstract_t">Leduc L, Moise KJ Jr, Carpenter RJ Jr, Cano LE. Fetoplacental blood volume estimation in pregnancies with Rh alloimmunization. Fetal Diagn Ther 1990; 5:138.</a></li><li><a class="nounderline abstract_t">Nicolaides KH, Clewell WH, Rodeck CH. Measurement of human fetoplacental blood volume in erythroblastosis fetalis. Am J Obstet Gynecol 1987; 157:50.</a></li><li><a class="nounderline abstract_t">Catalano PM, Capeless EL. Fetomaternal bleeding as a cause of recurrent fetal morbidity and mortality. Obstet Gynecol 1990; 76:972.</a></li><li><a class="nounderline abstract_t">Maass B, Würfel B, Fusch C. Recurrent fetomaternal transfusion in two consecutive pregnancies. Prenat Diagn 2001; 21:791.</a></li><li><a class="nounderline abstract_t">Dupont G, Povlsen JV. [Repeated episodes of massive fetomaternal hemorrhage in the same woman]. Ugeskr Laeger 1991; 153:2750.</a></li></ol></div><div id="topicVersionRevision">Topic 6806 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3095989" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Fetomaternal transplacental hemorrhage during pregnancy and after delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8127519" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Massive fetomaternal hemorrhage: Manitoba experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19786783" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Fetal transfusion of red blood cells for alloimmunization: validity of a published equation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26866844" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Fetomaternal hemorrhage complicated pregnancy: risks, identification, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17666598" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Long-term prognosis for infants after massive fetomaternal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33961809" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Fetomaternal hemorrhage: evaluation of recurrence within a large integrated healthcare system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14629094" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Biological implications of bi-directional fetomaternal cell traffic: a summary of a National Institute of Child Health and Human Development-sponsored conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10973858" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Quantitative analysis of the bidirectional fetomaternal transfer of nucleated cells and plasma DNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29745271" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fetal Hemoglobin in the Maternal Circulation - Contribution of Fetal Red Blood Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/602720" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Feto-maternal bleeding. During pregnancy and at delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2190367" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Fetomaternal hemorrhage: incidence, risk factors, time of occurrence, and clinical effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7692044" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical application of the Kleihauer-Betke test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6421161" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Detection of fetal erythrocytes in maternal blood post partum with the fluorescence-activated cell sorter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4972435" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Significance of placental pathology in transplacental haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9178311" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Severe fetomaternal hemorrhage: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23196720" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Severe neonatal anemia from fetomaternal hemorrhage: report from a multihospital health-care system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11028590" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Limitations of ultrasound in the diagnosis of fetomaternal haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5490099" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Incompatible fetomaternal transfusion with maternal intravascular lysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/850565" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sinusoidal fetal heart rate pattern and severe fetal anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27174184" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Diagnosis of Severe Fetomaternal Hemorrhage with Fetal Cerebral Doppler: Case Series and Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2729377" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Heart rate patterns in normoxemic, hypoxemic, and anemic second-trimester fetuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24526231" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Impact of physician awareness on diagnosis of fetomaternal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7145257" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Fetomaternal bleeding as a cause for "unexplained" fetal death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26332994" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The contribution of massive fetomaternal hemorrhage to antepartum stillbirth: a 25-year cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12905516" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Doppler sonography for predicting fetal anemia caused by massive fetomaternal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20145386" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Sinusoidal heart rate patterns as a manifestation of massive fetomaternal hemorrhage in a monochorionic-diamniotic twin pregnancy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15210038" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Sinusoidal heart rate pattern: Reappraisal of its definition and clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6344269" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Sinusoidal versus pseudosinusoidal fetal heart rate patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25736586" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Two cases of asymptomatic massive fetomaternal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22709788" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinically silent massive fetomaternal hemorrhage: important lessons from an illustrative case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22166605" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Causes of death among stillbirths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32080052" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Management of Stillbirth: Obstetric Care Consensus No, 10.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20410781" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Fetomaternal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34408259" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Diagnostic accuracy of Kleihauer-Betke (Kb) testing to predict fetal outcomes associated with fetomaternal hemorrhage: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22231030" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Detection of fetomaternal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31173529" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Use of Fetal Hemoglobin Quantitation for Rh-Positive Pregnant Females: A National Survey and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13450287" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : [Demonstration of fetal hemoglobin in erythrocytes of a blood smear].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/70589" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pattern of maternal F-cell production during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17053464" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Detecting fetomaternal hemorrhage by flow cytometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9218154" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Measurement of feto-maternal haemorrhage: a comparative study of three Kleihauer techniques and tow flow cytometry methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22738617" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Heterogeneity of F cells inβ-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29072803" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The presence of F cells with a fetal phenotype in adults with hemoglobinopathies limits the utility of flow cytometry for quantitation of fetomaternal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16912488" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Successful in utero treatment of chronic and massive fetomaternal hemorrhage with fetal hydrops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25356213" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Two intrauterine rescue transfusions in treatment of severe fetomaternal hemorrhage in the early third trimester.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19145084" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Successful treatment of a severe second trimester fetomaternal hemorrhage by repeated fetal intravascular transfusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20410780" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Using middle cerebral artery peak systolic velocity to time in utero transfusions in fetomaternal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16157122" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Correlation between middle cerebral artery peak systolic velocity and fetal hemoglobin after 2 previous intrauterine transfusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19462175" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sonographic findings in severe fetomaternal transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30223274" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The Recurrence Risk of Fetomaternal Hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20204132" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Massive fetomaternal hemorrhage caused by an intraplacental choriocarcinoma: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24987912" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The clinical characteristics and early detection of postpartum choriocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19293586" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prenatal findings in a case of massive fetomaternal hemorrhage associated with intraplacental choriocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3449817" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Transplacental hemorrhage associated with placental neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17511805" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Intraplacental choriocarcinoma as an unexpected cause of intrauterine death at term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29620671" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Intraplacental choriocarcinoma coexisting with fetomaternal hemorrhage: Case report, chemotherapy management, and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26009026" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Severe pre-eclampsia and HELLP syndrome after massive fetomaternal hemorrhage following blunt abdominal trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2719146" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mechanisms of fetal blood volume restoration after slow fetal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2201211" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Fetal blood volume restoration following rapid fetal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2130838" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Fetoplacental blood volume estimation in pregnancies with Rh alloimmunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3605267" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Measurement of human fetoplacental blood volume in erythroblastosis fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2216268" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Fetomaternal bleeding as a cause of recurrent fetal morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11559918" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Recurrent fetomaternal transfusion in two consecutive pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1949290" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : [Repeated episodes of massive fetomaternal hemorrhage in the same woman].</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
